Investor Newsletter

Issue 10 2021

MicroPort®

Top-tier Surgical Robot Company MicroPort MedBot Debuts on Main Board of HKEX

Hong Kong SAR/ Shanghai China, 2 November 2021 — Shanghai MicroPort® MedBot (Group) Co., Ltd. (02252.HK, "MicroPort MedBot" or "Company"), a subsidiary of MicroPort Scientific Corporation (00853.HK, "MicroPort®") today successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited (HKEX).

Dr. Chao He, President of MicroPort MedBot, commented, "Thanks to the support of our controlling shareholder MicroPort® and various pre-IPO investors, MicroPort MedBot has achieved rapid growth and multiple breakthroughs in product development and registration. This listing on HKEX will provide significant financial support for continued strategic expansion in the five major and rapidly growing surgical specialties of surgical robots. In the future, MicroPort MedBot will continue to innovate and accelerate R&D and industrialization efforts to provide patients worldwide with total surgical solutions backed by robotic intelligence that can prolong and reshape lives. "

Mr. Hongbin Sun, Chief Financial Officer of MicroPort® and Chairman of the Board of MicroPort MedBot, stated, "The listing of MicroPort MedBot on HKEX is yet another important milestone for both MicroPort® and MicroPort MedBot. In the future, MicroPort MedBot will further strengthen its corporate governance, fulfill its mission, assume social responsibility, and devote itself to meeting the needs for cutting-edge minimally invasive surgery to serve patients while ensuring excellent performance to reciprocate the investor community. "

MicroPort

MicroPort® Makes Strategic Investment in Intravascular Imaging Start-up Argus

MicroPort Scientific Corporation (00853.HK, "MicroPort®") signed a strategic investment agreement with Suzhou Argus Medical Technology Co., ("Argus") and the related parties. Under the agreement, MicroPort® will directly invest in Argus and acquire part of the equity from the existing shareholders, with total cost of RMB 372.3 million. After completion of the transaction, MicroPort® will become the controlling shareholder of Argus, with 51% equity interest in Argus.

Argus Clarity ®

NOPURGE®



Dr. Lintao Zhang, CEO of Argus, said, "Our team was established with solid foundation in optical communication, and extend our step into the medical device industry. We are very pleased to have landed this partnership with MicroPort®, one of the leading players in the medical device industry. With the support of MicroPort®, we will maximize our team's strengths in optoelectronics engineering and large-scale industrialization to help reduce the cost of diagnosis and treatment and provide better therapeutic services to patients."

Lei Jiang, Senior Vice President of Coronary Marketing Business in China and Chairman of the Board of MicroImaging (Shenzhen) Medical Equipment Co., Ltd. ("MicroImaging"), a wholly-owned subsidiary of MicroPort®, said, "PCI precision treatments such as intravascular imaging have become a trend. In addition to the early efforts in cardiovascular robotics and artificial intelligence, MicroPort® has formed a strategic partnership with Siemens to jointly develop a China-made DSA system last year. The strategic investment in Argus will further strengthen MicroPort®'s product footprint in the vascular interventional imaging industry, providing more integrated and precision diagnosis and total solutions in pan-vascular field, which will play an indispensable synergistic role in clinical implantation evaluation and follow-up observation during the large-scale promotion and application of MicroPort®'s Firesorb® Bioresorbable Rapamycin Targeted Eluting Coronary Scaffold System in the future. According to the agreement, MicroPort® will be fully responsible for marketing application of Argus products. We will leverage our existing channels, services and clinical resources, alongside the OCT products of Argus and its expertise in imaging technology, to provide patients with coronary artery diseases with integrative solutions that can extend and reshape their lives."

MicroPort

Construction Begins on 280,000-Square-Meter MicroPort® MegaFactory and Global Medical Experience Center

Recently, MicroPort Scientific Corporation (00853.HK, "MicroPort®") signed construction agreement with Zhejiang Construction Engineering Group Co., Ltd. ("Zhejiang Construction Engineering, ZCE") to expand the Jiaxing MicroPort® Campus in Jiaxing Science and Technology City and to become a high throughput production base and MicroPort® Global Medical Experience Center. The construction is expected to be completed by 2025.

Mr. Yiyun Que, Senior Vice President of Intelligent Manufacturing and Global Supply Chain at MicroPort®, noted, "The MicroPort® MegaFactory, once completed, will effectively alleviate the increasingly urgent and heavy demand for production space posed by the various business operations under the current strategic landscape of MicroPort®. In line with China's Yangtze River Delta integration strategy, the R&D and manufacturing centers of MicroPort® in Shanghai, Suzhou and Jiaxing form our own unique 'MicroPort® Yangtze River Delta', which allows the free flow of MicroPort®'s internal resources, such as innovation, production and marketing, within the Yangtze River Delta to significantly improve the operational efficiency of the company. We believe this project will not only help improve the positioning and development of MicroPort® in the Yangtze River Delta region but also contribute to the promotion of the high-performance medical device industry in Jiaxing, bringing economic and social benefits to the local communities. "

Mr. Yimin Xu, Executive Vice President of Product Registration and Property Management at MicroPort®, said, "Once the MicroPort® MegaFactory is brought into operation, it is expected to solve the capacity bottleneck that our subsidiaries are facing. Meanwhile, MicroPort® will make full use of this large-scale infrastructure to strengthen the development of an integrated platform for high-end medical devices, with an aim to provide more high-quality, integrated medical solutions for patients and doctors worldwide. "

MicroPort

MicroPort® Expands MIH in Suzhou Industrial Park to Build Strategic Strength for Original Innovation of High-Tech Medical Solutions

MicroPort Institute of Health (MIH), a division of MicroPort Scientific Corporation (MicroPort®), has officially launched its expansion project in Suzhou, China. The expansion is expected to provide additional platforms for comprehensive basic research to further strengthen the foundation for MicroPort® to develop its core businesses in the medium to long term.

Dr. Chengyun Yue, the First Vice President of Business Development and Project Management of MicroPort®, commented, "MIH is an important component of MicroPort®'s long-term strategy and unique business model. Through persistent effort, MicroPort® hopes to gain an advantageous position in the global medical industry in terms of intellectual property and technology. Meanwhile, MIH will further leverage the strengths of manufacturers, academic institutions, research centers, hospitals, and businesses in the YRD to create multiple comprehensive platforms for basic research as well as channels for international cooperation. This will also help attract and develop talents for the health industry, and at the same time create the right environment for top institutions and experts to carry out research and innovation."

MicroPort

MicroPort® Orthopedics Receives FDA 510(k) Approval for Two Hip Products

The Dynasty® Dual Mobility Acetabular Liners and the E-Class® Vitamin E Blended Dual Mobility Inserts, both independently developed and designed by MicroPort® Orthopedics received 510(k) approval from the US Food and Drug Administration (FDA) for marketing in the United States.

The Dynasty® Dual Mobility Acetabular Cup System is an artificial joint prosthesis designed and developed to mimic the physiological structure of the human hip joint. It consists of a metal shell and a highly cross-linked polyethylene liner, effectively reducing the rate of dislocation during hip replacement procedures. The Vitamin E blended polyethylene material can prevent the acetabular liner from oxidation and enhance its wear resistance, which is especially recommended for elderly people who need to undergo repair surgeries for hip fractures or hip revisions, as well as for patients with neuromuscular diseases with a high risk of dislocation. It helps increase the stability and mobility of the hip joint after surgery and offers the possibility of achieving a "zero" acetabulum dislocation rate in clinical practices.

MicroPort® CRM Announces Completion of Patient Recruitment for the Primary Objectives of the Apollo Study on Invicta Defibrillation Lead

MicroPort CRM, a pioneering company in Cardiac Rhythm Management (CRM) headquartered in France with global operations, today announced the completion of patient recruitment in the Apollo clinical study aimed at meeting the primary objectives. Apollo is a pre-market study assessing the safety and efficacy of the Invicta defibrillation lead. The main objectives are evaluated on the first 157 patients followed for 3 months. Since the study began in June 2021, 33 European centers have been involved.

Principal investigator of the Apollo study, Dr Pedro Marques of Santa Maria Hospital, Lisbon, commented, "I am very satisfied with the way this study is being conducted. The first 157 inclusions have been reached more than a month ahead of the initial schedule, made possible thanks to the very good performance of the Invicta lead during the implantation procedure, as well as the great contribution of the centers participating in the study. I would like to thank all the investigators for their involvement".

Benoît Clinchamps, President of MicroPort CRM, commented, “The Apollo Study is a key milestone for MicroPort CRM, which we will use as a cornerstone to build a new line of implantable defibrillation systems, including both devices and leads, 1.5 and 3 Tesla MRI conditional and equipped with the advanced features that characterize our products, including an outstanding longevity. Thanks to our technology and the strengthening of our commercial offering, we have a good growth perspective ahead of us, with Invicta expected to be marketed for the first time in Europe in 2022, followed by Japan, after obtaining regulatory certifications”.

MicroPort



Clinical Trial Enrollment Completed for the First Endovastec™ Venous Stent

Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd. (Endovastec™) recently completed the final procedure of the pre-market multicenter clinical trial for the Vflower® Venous Stent System in Beijing, marking the completion of patient enrollment in the trial. The clinical trial for the Vflower® Venous Stent System is a prospective, multi-center, single-arm, nationwide clinical study led by Peking Union Medical College Hospital, in conjunction with The Affiliated Hospital of Qingdao University, and 12 medical centers as co-participators in China. It took just 10 months from the first implantation to the enrollment completion.

Dr. Zhenyu Yuan, Vice President of Endovastec™ and General Manager of Bluevastec™, stated, "Bluevastec™ will continue to focus on developing more venous products and strengthen its product portfolio in this space through in-depth basic research and rich clinical research data to offer more cost-effective solutions for more patients with venous diseases."

MicroPort

CardioFlow Medtech Increases Investment in US Structural Heart Disease Innovator 4C Medical

MicroPort CardioFlow Medtech Corporation (02160.HK, CardioFlow Medtech) is set to become the largest shareholder of 4C Medical Technologies, Inc. (4C Medical) following the recent completion of a series C preferred shares subscription agreement. As the lead investor of the round, CardioFlow Medtech will make a strategic investment up to USD 25 million in 4C Medical, and will be granted the exclusive commercial rights to the investigational tricuspid products in China.

Mr. Guoming Chen, President of CardioFlow Medtech, commented, "CardioFlow Medtech has previously invested in 4C Medical and became a shareholder back in 2018, and with this round of strategic investment, we will further strengthen our cooperation and be granted exclusive commercial rights of the investigational tricuspid products in China. The move will further enrich CardioFlow Medtech's product pipeline in mitral and tricuspid valve interventions, which will complement our diversified product portfolio, enhance our market competitiveness and provide a comprehensive structural heart diseases treatment solutions for patients worldwide."

4C MEDICAL



MicroPort

Multicenter Clinical Trial Kicks Off for MicroPort® Toumai® Laparoscopic Surgery Robot

The multi-center clinical trial, 'Robotic-assisted thoracic, abdominal and pelvic procedures using the Toumai Endoscopic Surgical System, registered by Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot) has completed the first surgery for an enrolled patient. The surgery, completed at the Sir Run Run Shaw Hospital, affiliated to Zhejiang University School of Medicine, marked the official kick-off of the multi-specialty, multi-center clinical study, which uses the MicroPort® Toumai® Laparoscopic Surgery Robot (Toumai®) in hepato-biliary-gastroenterological surgeries, thoracic surgeries, and gynecology.

MicroPort® MedBot is a subsidiary of MicroPort Scientific Corporation (0853.HK, MicroPort®). MicroPort® started its strategic development of medical robots in 2014 and has since been engaged in independent research and development of endoscopic surgical robots. Over the years, MicroPort® MedBot has focused on the development and commercialization of minimally invasive and noninvasive surgical robots, with integrated solutions gradually created for multiple clinical applications on five 'golden paths', namely laparoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture.

MicroPort

MicroPort® MedBot Enters into Strategic Cooperation Agreement with South China Hospital affiliated to Shenzhen University

Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot) recently held a signing ceremony to mark the strategic cooperation agreement with South China Hospital affiliated to Shenzhen University and a project initiation meeting for a clinical research program of Toumai® Laparoscopic Surgical Robot.

Mr. Yu Liu stated, "This is the first time that MicroPort® MedBot has partnered with a public hospital in Shenzhen. MicroPort® MedBot will work with South China Hospital to promote technological research and application development of minimally invasive robotic surgery, and conduct exploratory clinical treatment research within regulatory boundaries using multidisciplinary robotics, including endoscopic surgical instrument control systems and orthopedic surgery navigation and positioning systems. "

President Song Wu noted, "It is one of the priorities of South China Hospital to build a pilot for medical robots. As the next step, South China Hospital will concentrate on strategizing and promoting innovation development. Guided by clinical solutions, we will actively carry out medical innovation, strengthen medical-industrial-academic-research cooperation for science and innovation through interdisciplinary cooperation, and promote the commercialization of medical innovations. It is our hope to promote high-level and high-quality development of the hospital through technology transformation and innovation. "

MicroPort

First DSA System of MicroImaging® Receives NMPA Marketing Approval

Soul-Man™, a Medical X-ray Angiography System jointly developed by MicroImaging (Shenzhen) Medical Equipment Co., Ltd. (MicroImaging®), a subsidiary of MicroPort Scientific Corporation (MicroPort®), and Siemens Healthineers, has received approval for marketing by China's National Medical Products Administration (NMPA).

Mr. Lei Jiang, Chairman of the Board of MicroImaging®, stated, "The approval of our first product signals MicroImaging®'s entry into the realm of precision medical imaging, as well as our first move towards developing collaborations with primary care facilities. This is a significant step forward in the evolution of MicroImaging®. In the future, MicroImaging® will continue to adhere to MicroPort®'s brand philosophy of, 'The Patient Always Comes First', and strive to provide accessible medical solutions for precision diagnosis to benefit patients."

Investor Newsletter

Issue 10 2021

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com